doi: 10.1161/hc3801.096325
(Circulation. 2001;104:1477.)
© 2001 American Heart Association, Inc.
Clinical Investigation and Reports |
Left Ventricular Muscle Mass and Elevated Heart Rate Are Associated With Coronary Plaque Disruption
From the Department of Cardiology, Pneumology, and Angiology, School of Internal Medicine, Heinrich-Heine-University, Düsseldorf, Germany.
Correspondence to Dr med Ulrich E. Heidland, Department of Cardiology, Pneumology, and Angiology, Heinrich-Heine-University, Moorenstr 5, D-40225 Düsseldorf, Germany. E-mail heidland{at}med.uni-duesseldorf.de
Background— Plaque disruption is the central pathophysiological mechanism underlying acute coronary syndromes and the progression of coronary atherosclerosis. There exists only scant information about the factors that are associated with its development. The aim of the current study was to analyze the contribution of hemodynamic forces in the pathogenesis of plaque disruption. Plaque disruption was diagnosed by coronary angiography of stenosed but not completely occluded coronary arteries.
Methods and Results— This study retrospectively analyzed 106 patients who underwent 2 coronary angiography procedures within 6 months. We investigated 53 patients with initially smooth stenoses who developed plaque disruption by the time of the second coronary angiogram and compared these patients with 53 age- and sex-matched individuals with smooth stenoses without angiographic signs of plaque disruption. The 2 groups were compared by analyzing central hemodynamics, echocardiographic measurements, and cardiovascular medication use. Logistic regression analysis identified positive associations between plaque disruption, left ventricular muscle mass >270 g, and a mean heart rate >80 bpm and a negative association with the use of ß-blockers.
Conclusions— The associations documented by our investigation indicate that hemodynamic forces may play a crucial role in the pathogenesis of plaque disruption. These findings may help to identify patients who are at an increased risk of plaque disruption and who might gain benefit from pharmacological interventions aimed at reducing heart rate, for example, by the use of ß-blockers, or a reduction of left ventricular hypertrophy.
Key Words: plaque • heart rate • hypertrophy • receptors, adrenergic, &bgr • coronary disease
This article has been cited by other articles:
 |
|
 |
|
  K. Fox, I. Ford, Ph. G. Steg, M. Tendera, M. Robertson, R. Ferrari, and on behalf of the BEAUTIFUL Investigators Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial Eur. Heart J., October 1, 2009; 30(19): 2337 - 2345. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-C. Tardif Heart rate and atherosclerosis Eur. Heart J. Suppl., August 1, 2009; 11(suppl_D): D8 - D12. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. G. Steg Heart rate management in coronary artery disease: the CLARIFY registry Eur. Heart J. Suppl., August 1, 2009; 11(suppl_D): D13 - D18. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Faria, R. S. Moraes, D. C. Sobral-Filho, A. G. Rego, M. F.P. Baracho, E. S.T. Egito, and J. Brandao-Neto Autonomic modulation in patients with congenital generalized lipodystrophy (Berardinelli-Seip syndrome) Europace, June 1, 2009; 11(6): 763 - 769. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Sajadieh A new combination therapy in stable angina pectoris Eur. Heart J., March 1, 2009; 30(5): 524 - 525. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Gopinathannair, R. M. Sullivan, and B. Olshansky Slower Heart Rates for Healthy Hearts: Time to Redefine Tachycardia? Circ Arrhythm Electrophysiol, December 1, 2008; 1(5): 321 - 323. [Full Text] [PDF]
|
|
|
|
 |
|
 B. M. Biccard and S. J. Howell Calcium channel blockers, beta-blockers, and perioperative cardiovascular stability Br. J. Anaesth., October 1, 2008; 101(4): 439 - 441. [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Carney, B. Steinmeyer, K. E. Freedland, J. A. Blumenthal, P. K. Stein, W. A. Steinhoff, W. B. Howells, L. F. Berkman, L. L. Watkins, S. M. Czajkowski, et al. Nighttime Heart Rate and Survival in Depressed Patients Post Acute Myocardial Infarction Psychosom Med, September 1, 2008; 70(7): 757 - 763. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Borer Heart rate: from risk marker to risk factor Eur. Heart J. Suppl., August 1, 2008; 10(suppl_F): F2 - F6. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Ferrari, C. Ceconi, and G. Guardigli Pathophysiological role of heart rate: from ischaemia to left ventricular dysfunction Eur. Heart J. Suppl., August 1, 2008; 10(suppl_F): F7 - F10. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-C. Tardif The pivotal role of heart rate in clinical practice: from atherosclerosis to acute coronary syndrome Eur. Heart J. Suppl., August 1, 2008; 10(suppl_F): F11 - F16. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Custodis, M. Baumhakel, N. Schlimmer, F. List, C. Gensch, M. Bohm, and U. Laufs Heart Rate Reduction by Ivabradine Reduces Oxidative Stress, Improves Endothelial Function, and Prevents Atherosclerosis in Apolipoprotein E-Deficient Mice Circulation, May 6, 2008; 117(18): 2377 - 2387. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. M. Biccard, J. W. Sear, and P. Foex Meta-analysis of the effect of heart rate achieved by perioperative beta-adrenergic blockade on cardiovascular outcomes Br. J. Anaesth., January 1, 2008; 100(1): 23 - 28. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Hjalmarson Heart rate: an independent risk factor in cardiovascular disease Eur. Heart J. Suppl., September 1, 2007; 9(suppl_F): F3 - F7. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Fox, J. S. Borer, A. J. Camm, N. Danchin, R. Ferrari, J. L. Lopez Sendon, P. G. Steg, J.-C. Tardif, L. Tavazzi, M. Tendera, et al. Resting Heart Rate in Cardiovascular Disease J. Am. Coll. Cardiol., August 28, 2007; 50(9): 823 - 830. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Sipahi, E. M. Tuzcu, K. E. Wolski, S. J. Nicholls, P. Schoenhagen, B. Hu, C. Balog, M. Shishehbor, W. A. Magyar, T. D. Crowe, et al. {beta}-Blockers and Progression of Coronary Atherosclerosis: Pooled Analysis of 4 Intravascular Ultrasonography Trials Ann Intern Med, July 3, 2007; 147(1): 10 - 18. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. H. Tofler and J. E. Muller Triggering of Acute Cardiovascular Disease and Potential Preventive Strategies Circulation, October 24, 2006; 114(17): 1863 - 1872. [Full Text] [PDF]
|
|
|
|
|
|
S. Cook, M. Togni, M. C. Schaub, P. Wenaweser, and O. M. Hess High heart rate: a cardiovascular risk factor? Eur. Heart J., October 2, 2006; 27(20): 2387 - 2393. [Full Text] [PDF]
|
|
|
|
|
|
M. R. Rosen, A. Bucchi, and R. B. Robinson If modulation: perspectives in clinical medicine Eur. Heart J. Suppl., September 1, 2006; 8(suppl_D): D3 - D8. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-C. Tardif and C. Berry From coronary artery disease to heart failure: potential benefits of ivabradine Eur. Heart J. Suppl., September 1, 2006; 8(suppl_D): D24 - D29. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. H.H. Feringa, J. J. Bax, E. Boersma, M. D. Kertai, S. H. Meij, W. Galal, O. Schouten, I. R. Thomson, P. Klootwijk, M. R.H.M. van Sambeek, et al. High-Dose {beta}-Blockers and Tight Heart Rate Control Reduce Myocardial Ischemia and Troponin T Release in Vascular Surgery Patients Circulation, July 4, 2006; 114(1_suppl): I-344 - I-349. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. H.H. Feringa, V. H. van Waning, J. J. Bax, A. Elhendy, E. Boersma, O. Schouten, W. Galal, R. V. Vidakovic, M. J. Tangelder, and D. Poldermans Cardioprotective Medication Is Associated With Improved Survival in Patients With Peripheral Arterial Disease J. Am. Coll. Cardiol., March 21, 2006; 47(6): 1182 - 1187. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Saha and A. D Timmis Review: Diabetic autonomic dysfunction: adverse effects on presentation, management and outcomes of acute coronary syndromes The British Journal of Diabetes & Vascular Disease, September 1, 2005; 5(5): 260 - 264. [Abstract] [PDF]
|
|
|
|
|
|
M. Tendera Editorial: If inhibition: from pure heart reduction to treatment of stable angina Eur. Heart J. Suppl., September 1, 2005; 7(suppl_H): H3 - H6. [Full Text] [PDF]
|
|
|
|
|
|
R. Ferrari, G. Campo, E. Gardini, G. Pasanisi, and C. Ceconi Specific and selective If inhibition: expected clinical benefits from pure heart rate reduction in coronary patients Eur. Heart J. Suppl., September 1, 2005; 7(suppl_H): H16 - H21. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Borer Heart rate slowing by If inhibition: therapeutic utility from clinical trials Eur. Heart J. Suppl., September 1, 2005; 7(suppl_H): H22 - H28. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Fox Future perspectives of If inhibition in various cardiac conditions Eur. Heart J. Suppl., September 1, 2005; 7(suppl_H): H33 - H36. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Palatini Heart rate: a strong predictor of mortality in subjects with coronary artery disease Eur. Heart J., May 2, 2005; 26(10): 943 - 945. [Full Text] [PDF]
|
|
|
|
|
|
A. Diaz, M. G. Bourassa, M.-C. Guertin, and J.-C. Tardif Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease Eur. Heart J., May 2, 2005; 26(10): 967 - 974. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Carney, K. E. Freedland, and R. C. Veith Depression, the Autonomic Nervous System, and Coronary Heart Disease Psychosom Med, May 1, 2005; 67(Supplement_1): S29 - S33. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Danchin If current inhibition with ivabradine: further perspectives Eur. Heart J. Suppl., September 1, 2003; 5(suppl_G): G52 - G56. [Abstract] [PDF]
|
|
|
|
 |
|
 J. H. O'Keefe Jr and B. M. Curtis Autonomic Tone and Benefits of Cardiac Rehabilitation Programs-Reply-I Mayo Clin. Proc., April 1, 2002; 77(4): 399 - 399. [PDF]
|
|
|
|
 |
|
 S. G. Myerson, N. G. Bellenger, and D. J. Pennell Assessment of Left Ventricular Mass by Cardiovascular Magnetic Resonance Hypertension, March 1, 2002; 39(3): 750 - 755. [Abstract] [Full Text] [PDF]
|
|